Cargando…
One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli
BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity althoug...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621789/ https://www.ncbi.nlm.nih.gov/pubmed/23557146 http://dx.doi.org/10.1186/1472-6750-13-32 |
_version_ | 1782265761911275520 |
---|---|
author | Caldinelli, Laura Albani, Diego Pollegioni, Loredano |
author_facet | Caldinelli, Laura Albani, Diego Pollegioni, Loredano |
author_sort | Caldinelli, Laura |
collection | PubMed |
description | BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of α-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate α-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-α-synuclein. RESULTS: A reliable protocol was designed to efficiently express and purify two different forms of human α-synuclein. The synthetic cDNAs encoding for the native α-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (≥ 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant α-synuclein protein forms could be purified in a single step to ≥ 95% purity. Both α-synuclein recombinant proteins form fibrils and the TAT-α-synuclein is also cytotoxic in the micromolar concentration range. CONCLUSIONS: To further characterize the molecular mechanisms of α-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular α-synuclein for the pathogenesis and progression of Parkinson’s disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant α-synuclein than previously described procedures. |
format | Online Article Text |
id | pubmed-3621789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36217892013-04-10 One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli Caldinelli, Laura Albani, Diego Pollegioni, Loredano BMC Biotechnol Research Article BACKGROUND: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that α-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of α-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate α-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-α-synuclein. RESULTS: A reliable protocol was designed to efficiently express and purify two different forms of human α-synuclein. The synthetic cDNAs encoding for the native α-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (≥ 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant α-synuclein protein forms could be purified in a single step to ≥ 95% purity. Both α-synuclein recombinant proteins form fibrils and the TAT-α-synuclein is also cytotoxic in the micromolar concentration range. CONCLUSIONS: To further characterize the molecular mechanisms of α-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular α-synuclein for the pathogenesis and progression of Parkinson’s disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant α-synuclein than previously described procedures. BioMed Central 2013-04-04 /pmc/articles/PMC3621789/ /pubmed/23557146 http://dx.doi.org/10.1186/1472-6750-13-32 Text en Copyright © 2013 Caldinelli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Caldinelli, Laura Albani, Diego Pollegioni, Loredano One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title_full | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title_fullStr | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title_full_unstemmed | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title_short | One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli |
title_sort | one single method to produce native and tat-fused recombinant human α-synuclein in escherichia coli |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621789/ https://www.ncbi.nlm.nih.gov/pubmed/23557146 http://dx.doi.org/10.1186/1472-6750-13-32 |
work_keys_str_mv | AT caldinellilaura onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli AT albanidiego onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli AT pollegioniloredano onesinglemethodtoproducenativeandtatfusedrecombinanthumanasynucleininescherichiacoli |